Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole. Approximate 60 patients will be recruited to achieve at least 40 evaluable patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Hyperprolactinemia Weight Gain Dyslipidemia |
Drug: Abilify (aripiprazole) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | February 2009 |
A.Screening / Baseline visit (V1; Day 0) After signing the informed consent form, patients' DSM-IV multiaxial examination, physical examination, vital sign, pregnancy test, BMI will be conducted. The demographics, medical history, and concomitant medication will be recorded. After evaluating all variables obtained, the eligible patients will be enrolled into study.Patients who fulfill the inclusion / exclusion criteria will be performed the laboratory tests, PANSS, EPS (AIMS & BARS), menstrual function, sexual function (Arizona sexual experience scale) and prolaction. Afterwards, the treatment period will be started to add-on with first medication (7.5 or 15 mg daily by patient, which was prescribed by investigator) to current antipsychotics at this visit. Besides, drug accounting and adverse events will also be recorded at this visit. Patients are maintained on current doses of antipsychotics, and all other medicines.
B.Treatment phase (V2~V3; 2~4 Week finished; 14±3~28±3 Day finished) The vital sign, physical examination, BMI, laboratory tests (at V3), PANSS, EPS (AIMS & BARS), menstrual function, sexual function (Arizona sexual experience scale), and prolactin will be carried out. Concomitant medication, adverse events, and drug accounting will also be recorded at this visit. Study drug could be titrated with a flexible dose from 7.5 to 30 mg QD. All dose adjustments should be made with the approval of the investigator.
C.Completion visit (V4; 8 Week Finished; 56±7 Day finished, or Early termination) The vital sign, physical examination, pregnancy test, BMI, laboratory tests, PANSS, EPS (AIMS & BARS), menstrual function, sexual function (Arizona sexual experience scale), prolactin will be carried out. Concomitant medication, adverse events, and drug accounting will also be recorded at this visit.
Eligibility| Ages Eligible for Study: | 12 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female in age between 12 and 65 years old.
- Clinical diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder with DSM-IV criteria.
- Keep stable dosage of the same antipsychotic other than aripiprazole during last one month.
- Who are currently taking antipsychotic drugs and for whom an alteration in medication is clinically reasonable. This includes patients who are stable or who have symptoms that are not optimally controlled or patients experiencing tolerability problems.
- Having antipsychotic-induced symptomatic hyperprolactinemia, weight gain, increased plasma glucose or dyslipidemia judged by the investigator.
- Informed Consent was obtained from the subject and legal guardian (if necessary).
Exclusion Criteria:
- Pregnant or breast feeding women or planning a pregnancy.
- Patient has a history of hypersensitivity or allergy to investigated drug.
- Acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention.
- Any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment.
- Having participated other investigational drug study and taken the investigation drug within one month prior to study entry.
Contacts and Locations| Contact: Chen Chih-Ken, PhD | +886-2-24313131 ext 3150 | kenchen@cgmh.org.tw |
| Principal Investigator: | Chen Chih-Ken, PhD | Chang Gung Memorial Hospital, Keelung, Taiwan |
More Information
No publications provided by Genovate Biotechnology Co., Ltd.,
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00541554 History of Changes |
| Other Study ID Numbers: | 31-06-P05 |
| Study First Received: | October 8, 2007 |
| Last Updated: | October 9, 2007 |
| Health Authority: | Taiwan: Institutional Review Board |
Additional relevant MeSH terms:
|
Hyperglycemia Hyperprolactinemia Weight Gain Dyslipidemias Glucose Metabolism Disorders Metabolic Diseases Hyperpituitarism Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases |
Body Weight Changes Body Weight Signs and Symptoms Lipid Metabolism Disorders Antipsychotic Agents Aripiprazole Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 16, 2013